Advicenne Past Earnings Performance
Past criteria checks 0/6
Advicenne has been growing earnings at an average annual rate of 8.9%, while the Pharmaceuticals industry saw earnings growing at 14% annually. Revenues have been growing at an average rate of 6.2% per year.
Key information
8.9%
Earnings growth rate
14.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 16.3% |
| Revenue growth rate | 6.2% |
| Return on equity | n/a |
| Net Margin | -264.9% |
| Last Earnings Update | 30 Jun 2024 |
Revenue & Expenses Breakdown
How Advicenne makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 3 | -9 | 4 | 5 |
| 31 Mar 24 | 3 | -8 | 4 | 5 |
| 31 Dec 23 | 3 | -7 | 4 | 4 |
| 30 Sep 23 | 3 | -9 | 4 | 5 |
| 30 Jun 23 | 3 | -10 | 4 | 6 |
| 31 Mar 23 | 3 | -11 | 5 | 7 |
| 31 Dec 22 | 3 | -11 | 5 | 7 |
| 30 Sep 22 | 3 | -10 | 5 | 7 |
| 30 Jun 22 | 4 | -9 | 5 | 7 |
| 31 Mar 22 | 4 | -11 | 6 | 8 |
| 31 Dec 21 | 4 | -12 | 6 | 9 |
| 30 Sep 21 | 4 | -14 | 5 | 6 |
| 30 Jun 21 | 4 | -15 | 8 | 8 |
| 31 Mar 21 | 4 | -15 | 9 | 8 |
| 31 Dec 20 | 3 | -15 | 9 | 8 |
| 30 Sep 20 | 3 | -15 | 11 | 11 |
| 30 Jun 20 | 3 | -15 | 4 | 1 |
| 31 Mar 20 | 2 | -14 | 4 | 0 |
| 31 Dec 19 | 3 | -14 | 8 | 9 |
| 30 Sep 19 | 2 | -11 | 6 | 5 |
| 30 Jun 19 | 2 | -8 | 5 | 1 |
| 31 Mar 19 | 1 | -6 | 4 | 1 |
| 31 Dec 18 | 1 | -5 | 3 | 0 |
| 30 Sep 18 | 2 | -6 | 3 | 3 |
| 30 Jun 18 | 2 | -7 | 4 | 6 |
| 31 Mar 18 | 2 | -7 | 4 | 5 |
| 31 Dec 17 | 3 | -6 | 3 | 5 |
| 30 Sep 17 | 2 | -5 | 3 | 4 |
| 30 Jun 17 | 2 | -4 | 2 | 4 |
| 31 Mar 17 | 2 | -4 | 2 | 4 |
| 31 Dec 16 | 2 | -4 | 2 | 3 |
| 31 Dec 15 | 3 | -2 | 1 | 0 |
| 31 Dec 14 | 2 | -2 | 1 | 0 |
Quality Earnings: ALDVI is currently unprofitable.
Growing Profit Margin: ALDVI is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ALDVI is unprofitable, but has reduced losses over the past 5 years at a rate of 8.9% per year.
Accelerating Growth: Unable to compare ALDVI's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ALDVI is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-19.9%).
Return on Equity
High ROE: ALDVI's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.